{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:26:25Z","timestamp":1714091185494},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,25]]},"DOI":"10.7759\/cureus.58972","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:52:49Z","timestamp":1714035169000},"source":"Crossref","is-referenced-by-count":0,"title":["Concomitant L248V With E225V Mutation in the BCR-ABL Gene Associated With Rapid Chronic Myeloid Leukemia Lymphoid Blast Crisis"],"prefix":"10.7759","author":[{"given":"Songphol","family":"Tungjitviboonkun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawitthorn","family":"Wachirapornpruet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorrawit","family":"Unsuwan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley JD","year":"1973","unstructured":"Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973, 243:290-93. 10.1038\/243290a0","journal-title":"Nature"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.07.007","article-title":"Epidemiology of chronic myeloid leukaemia (CML)","volume":"22","author":"Rohrbacher M","year":"2009","unstructured":"Rohrbacher M, Hasford J. Epidemiology of chronic myeloid leukaemia (CML). Best Pract Res Clin Haematol. 2009, 22:295-302. 10.1016\/j.beha.2009.07.007","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, et al.. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020, 34:966-84. 10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90754-6","article-title":"Chronic myelogenous leukemia in blast crisis: analysis of 242 patients","volume":"83","author":"Kantarjian HM","year":"1987","unstructured":"Kantarjian HM, Keating MJ, Talpaz M, et al.. Chronic myelogenous leukemia in blast crisis: analysis of 242 patients. Am J Med. 1987, 83:445-54. 10.1016\/0002-9343(87)90754-6","journal-title":"Am J Med"},{"key":"ref5","doi-asserted-by":"crossref","DOI":"10.1016\/S0308-2261(21)00550-6","article-title":"The clinical features of chronic granulocytic leukaemia","volume":"6","author":"Spiers AS","year":"1977","unstructured":"Spiers AS. The clinical features of chronic granulocytic leukaemia. Clin Haematol. 1977, 6:77-95.","journal-title":"Clin Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann VS","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, et al.. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015, 29:1336-43. 10.1038\/leu.2015.73","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow SH","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al.. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016, 127:2375-90. 10.1182\/blood-2016-01-643569","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes JE","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al.. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-na\u00efve chronic myeloid leukemia patients trial. J Clin Oncol. 2016, 34:2333-40. 10.1200\/JCO.2015.64.8899","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus A","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, et al.. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016, 30:1044-54. 10.1038\/leu.2016.5","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13108","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial","volume":"168","author":"Br\u00fcmmendorf TH","year":"2015","unstructured":"Br\u00fcmmendorf TH, Cortes JE, de Souza CA, et al.. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015, 168:69-81. 10.1111\/bjh.13108","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-05-1816","article-title":"Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"107","author":"Jabbour E","year":"2006","unstructured":"Jabbour E, Kantarjian H, O'Brien S, et al.. Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. Blood. 2006, 107:480-2. 10.1182\/blood-2005-05-1816","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.302","article-title":"Lymphoid blast crisis after prolonged treatment-free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de-escalation during the COVID-19 pandemic","volume":"3","author":"Avenoso D","year":"2022","unstructured":"Avenoso D, Milojkovic D, Clark J, Pocock C, Potter V, Yallop D, Hannah G. Lymphoid blast crisis after prolonged treatment-free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de-escalation during the COVID-19 pandemic. EJHaem. 2022, 3:215-7. 10.1002\/jha2.302","journal-title":"EJHaem"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0123","article-title":"Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia","volume":"102","author":"Huntly BJ","year":"2003","unstructured":"Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood. 2003, 102:1160-8. 10.1182\/blood-2003-01-0123","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson B","year":"2002","unstructured":"Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol. 2002, 107:76-94. 10.1159\/000046636","journal-title":"Acta Haematol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404400","article-title":"A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib","volume":"20","author":"Gruber FX","year":"2006","unstructured":"Gruber FX, Hjorth-Hansen H, Mikkola I, Stenke L, Johansen T. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia. 2006, 20:2057-60. 10.1038\/sj.leu.2404400","journal-title":"Leukemia"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2008.11.012","article-title":"Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia","volume":"190","author":"Park TS","year":"2009","unstructured":"Park TS, Cheong JW, Kim SJ, et al.. Concomitant t(3;3)(q21;q26), trisomy 19, and E255V mutation associated with imatinib mesylate resistance in chronic myelogenous leukemia. Cancer Genet Cytogenet. 2009, 190:46-8. 10.1016\/j.cancergencyto.2008.11.012","journal-title":"Cancer Genet Cytogenet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes J","year":"2007","unstructured":"Cortes J, Jabbour E, Kantarjian H, et al.. Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood. 2007, 110:4005-11. 10.1182\/blood-2007-03-080838","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-015347","article-title":"Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study","volume":"109","author":"Ray A","year":"2007","unstructured":"Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007, 109:5011-5. 10.1182\/blood-2006-01-015347","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review","volume":"34","author":"An X","year":"2010","unstructured":"An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010, 34:1255-68. 10.1016\/j.leukres.2010.04.016","journal-title":"Leuk Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1089\/gtmb.2012.0147","article-title":"ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan","volume":"16","author":"Awidi A","year":"2012","unstructured":"Awidi A, Ababneh N, Magablah A, Bsoul N, Mefleh R, Marei L, Abbasi S. ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan. Genet Test Mol Biomarkers. 2012, 16:1317-21. 10.1089\/gtmb.2012.0147","journal-title":"Genet Test Mol Biomarkers"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/250412-concomitant-l248v-with-e225v-mutation-in-the-bcr-abl-gene-associated-with-rapid-chronic-myeloid-leukemia-lymphoid-blast-crisis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T08:52:52Z","timestamp":1714035172000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/250412-concomitant-l248v-with-e225v-mutation-in-the-bcr-abl-gene-associated-with-rapid-chronic-myeloid-leukemia-lymphoid-blast-crisis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,25]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.58972","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,25]]}}}